EL7.AI
Mergers & AcquisitionsMedium•23 July 2026•
1 min read

Instinct Bio to Debut on Nasdaq Following Relativity Acquisition Merger Completion

Key Facts

1Instinct Bio completed its business combination with Relativity Acquisition Corp. to begin trading on Nasdaq under the ticker BIOT.
2The combined company has a pro forma enterprise value of approximately $288 million.
3The stock is scheduled to commence trading on the U.S. public markets on July 24, 2026.

In a move reflecting the ongoing expansion of the regenerative medicine sector, Instinct Bio has completed its merger with Relativity Acquisition Corp to become a publicly traded entity. The company's shares are scheduled to commence trading on the Nasdaq Stock Market under the ticker BIOT starting July 24, 2026. This business combination is designed to provide the company with access to public capital markets to fund the development of its regenerative medicine and longevity platform.

The debut follows the establishment of a pro forma enterprise value for the combined company of approximately $288 million. Through this merger, the firm will operate as a global platform specializing in cell-based therapies, evolving from its Tokyo-based origins into a U.S.-listed innovator. According to reports, this listing represents a defining moment in the company's institutional evolution and its transition toward global operations.

Investors will be watching the company's ability to maintain Nasdaq listing standards and realize anticipated merger benefits amid competition in the biotech sector. Current economic calendars show no direct upcoming catalysts for the company within the immediate seven-day window following its debut.